Courts Rule On GLP-1 Shortage Row, 340B In Colo. And More
By Gianna Ferrarin · September 1, 2026, 7:53 PM EDT
A Fifth Circuit panel concluded that the U.S. Food and Drug Administration did not unlawfully remove blockbuster GLP-1 medications made by Eli Lilly & Co. and Novo Nordisk from the national...
To view the full article, register now.